PMID- 37980483 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231124 IS - 1475-2867 (Print) IS - 1475-2867 (Electronic) IS - 1475-2867 (Linking) VI - 23 IP - 1 DP - 2023 Nov 18 TI - Discovery of a new marker to identify myeloid cells associated with metastatic breast tumours. PG - 279 LID - 10.1186/s12935-023-03136-w [doi] LID - 279 AB - BACKGROUND: Myeloid cells play an essential role in cancer metastasis. The phenotypic diversity of these cells during cancer development has attracted great interest; however, their functional heterogeneity and plasticity have limited their role as prognostic markers and therapeutic targets. METHODS: To identify markers associated with myeloid cells in metastatic tumours, we compared transcriptomic data from immune cells sorted from metastatic and non-metastatic mammary tumours grown in BALB/cJ mice. To assess the translational relevance of our in vivo findings, we assessed human breast cancer biopsies and evaluated the association between arginase 1 protein expression in breast cancer tissues with tumour characteristics and patient outcomes. RESULTS: Among the differentially expressed genes, arginase 1 (ARG1) showed a unique expression pattern in tumour-infiltrating myeloid cells that correlated with the metastatic capacity of the tumour. Even though ARG1-positive cells were found almost exclusively inside the metastatic tumour, ARG1 protein was also present in the plasma. In human breast cancer biopsies, the presence of ARG1-positive cells was strongly correlated with high-grade proliferating tumours, poor prognosis, and low survival. CONCLUSION: Our findings highlight the potential use of ARG1-positive myeloid cells as an independent prognostic marker to evaluate the risk of metastasis in breast cancer patients. CI - (c) 2023. The Author(s). FAU - Bokil, Ansooya A AU - Bokil AA AD - Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. AD - Centre of Molecular Inflammation Research (CEMIR), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Le Boulvais Borkja, Mathieu AU - Le Boulvais Borkja M AD - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Wolowczyk, Camilla AU - Wolowczyk C AD - Centre of Molecular Inflammation Research (CEMIR), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. AD - Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Lamsal, Apsana AU - Lamsal A AD - Centre of Molecular Inflammation Research (CEMIR), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. AD - Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Prestvik, Wenche S AU - Prestvik WS AD - Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Nonstad, Unni AU - Nonstad U AD - Centre of Molecular Inflammation Research (CEMIR), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Pettersen, Kristine AU - Pettersen K AD - Centre of Molecular Inflammation Research (CEMIR), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. AD - Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Andersen, Sonja B AU - Andersen SB AD - Centre of Molecular Inflammation Research (CEMIR), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. AD - Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Bofin, Anna M AU - Bofin AM AD - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Bjorkoy, Geir AU - Bjorkoy G AD - Centre of Molecular Inflammation Research (CEMIR), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. AD - Department of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Hak, Sjoerd AU - Hak S AD - Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. AD - Department of Biotechnology and Nanomedicine, SINTEF, Trondheim, Norway. FAU - Giambelluca, Miriam S AU - Giambelluca MS AUID- ORCID: 0000-0003-0965-4943 AD - Centre of Molecular Inflammation Research (CEMIR), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. miriam.giambelluca@ntnu.no. AD - Department of Clinical Medicine, Faculty of Health Science, UiT- The Arctic University of Norway, Tromso, Norway. miriam.giambelluca@ntnu.no. LA - eng GR - 314984/Norges Forskningsrad/ GR - 314984/Norges Forskningsrad/ GR - 223255/F50/Research Council of Norway (Centres of Excellence funding program)/ GR - 223255/F50/Research Council of Norway (Centres of Excellence funding program)/ GR - 223255/F50/Research Council of Norway (Centres of Excellence funding program)/ PT - Journal Article DEP - 20231118 PL - England TA - Cancer Cell Int JT - Cancer cell international JID - 101139795 PMC - PMC10656772 OTO - NOTNLM OT - Arginase 1 OT - Metastatic tumours OT - Myeloid-derived cells OT - Prognostic marker COIS- The authors declare no competing interests. EDAT- 2023/11/19 09:43 MHDA- 2023/11/19 09:44 PMCR- 2023/11/18 CRDT- 2023/11/19 02:12 PHST- 2023/05/26 00:00 [received] PHST- 2023/11/10 00:00 [accepted] PHST- 2023/11/19 09:44 [medline] PHST- 2023/11/19 09:43 [pubmed] PHST- 2023/11/19 02:12 [entrez] PHST- 2023/11/18 00:00 [pmc-release] AID - 10.1186/s12935-023-03136-w [pii] AID - 3136 [pii] AID - 10.1186/s12935-023-03136-w [doi] PST - epublish SO - Cancer Cell Int. 2023 Nov 18;23(1):279. doi: 10.1186/s12935-023-03136-w.